ESMO® 2026 Highlights: Presenter Vignettes – Hiroya Taniguchi

Dr. Hiroya Taniguchi

Hiroya Taniguchi

MD, PhD

Aichi Cancer Center Hospital

LBA31

Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial